According to the Complaint, Ohr Pharmaceutical, Inc. is a clinical-stage pharmaceutical company that develops novel therapies for ophthalmic diseases.

This action stems from a proposed transaction announced on January 3, 2019 (the “Proposed Transaction”), pursuant to which Ohr Pharmaceutical, Inc. will merge with NeuBase Therapeutics, Inc.

On March 8 2019, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on March 23, 2022.